Contact_NN
information_NOMZ
Registered_NN
office_NN
and_CC
corporate_JJ
headquarters_NN
address_NN
AstraZeneca_NN
PLC_NN
15_CD
Stanhope_NN
Gate_NN
London_NN
W1K_NN
1LN_NN
UK_NN
Tel_NN
:_:
44_CD
0_CD
20 7304 5000_CD
Fax_NN
:_:
44_CD
0_CD
20 7304 5183_CD
R&D_NN
headquarters_NN
address_NN
AstraZeneca_NN
AB_NN
R&D_NN
Headquarters_NN
SE-151_NN
85_CD
Sdertlje_NN
Sweden_NN
Tel_NN
:_:
46_CD
0_CD
8_CD
553_CD
260_CD
00_CD
Fax_NN
:_:
46_CD
0_CD
8_CD
553_CD
290_CD
00_CD
Investor_NN
relations_NOMZ
contacts_NN
UK_NN
and_PHC
Sweden_NN
:_:
as_IN
above_PLACE
or_CC
e-mail_VB
IR@astrazeneca_NN
._.
com_NN
US_FPP1
:_:
Investor_NN
Relations_NOMZ
AstraZeneca_NN
Pharmaceuticals_NN
LP_NN
1800_CD
Concord_NN
Pike_NN
PO_NN
Box_NN
15438_CD
Wilmington_NN
fide_NN
19850-5438_CD
US_FPP1
Tel_NN
:_:
1_CD
302 886 3000_CD
Fax_NN
:_:
1_CD
302 886 2972_CD
Registrar_NN
and_CC
transfer_VB
office_NN
Lloyds_NN
TSB_NN
Registrars_NN
The_DT
Causeway_NN
Worthing_GER
West_NN
Sussex_NN
BN99_NN
6DA_NN
UK_NN
Tel_NN
in_PIN
the_DT
UK_NN
:_:
0870 600 3956_CD
Tel_NN
outside_PLACE
the_DT
UK_NN
:_:
44 121 415 7033_CD
Swedish_JJ
securities_NOMZ
registration_NOMZ
center_NN
VPC_NN
AB_NN
PO_NN
Box_NN
7822_CD
SE-103_NN
97_CD
Stockholm_NN
Sweden_NN
Tel_NN
:_:
46_CD
0_CD
8_CD
402_CD
9000_CD
US_FPP1
depositary_JJ
JPMorgan_NN
Chase_NN
Bank_NN
PO_NN
Box_NN
43013_CD
Providence_NN
RI_NN
02940-3013_CD
US_FPP1
Tel_NN
toll_NN
free_JJ
in_PIN
the_DT
US_FPP1
:_:
888 697 8018_CD
Tel_NN
:_:
1_CD
781 575 4328_CD
astrazeneca_NN
._.
com_NN
Annual_JJ
Review_NN
2004_CD
thinking_VBG [PRIV] [THATD]
people_NN
thinking_VBG [PRIV] [WZPRES]
performance_NN
Annual_JJ
Review_NN
2004_CD
01_CD
astrazeneca_NN
._.
com_NN
The_DT
year_NN
in_PIN
brief_JJ
AstraZeneca_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
worlds_NN
Group_NN
sales_NN
up_IN
9_CD
%_NN
at_PIN
constant_JJ
exchange_NN
rates_NN
to_TO
$_$
21.4_CD
billion_CD
strong_JJ
leading_VBG
pharmaceutical_JJ
companies_NN
._.
sales_NN
performance_NN
from_PIN
key_JJ
growth_NN
products_NN
up_IN
30_CD
%_NN
to_TO
$_$
11.2_CD
billion_CD
We_FPP1
focus_VB
our_FPP1
skills_NN
,_,
experience_NN
Operating_GER
profit_NN
up_RB
15_CD
%_NN
at_PIN
constant_JJ
exchange_NN
rates_NN
to_TO
$_$
4.8_CD
billion_CD
EPS_NN
and_PHC
resources_NN
on_PIN
six_CD
therapy_NN
pre-exceptional_JJ
items_NN
up_IN
18_CD
%_NN
areas_NN
:_:
cancer_NN
,_,
cardiovascular_JJ
,_,
gastrointestinal_JJ
,_,
infection_NOMZ
,_,
Dividend_NN
increased_VBN [WZPAST]
by_PIN
18_CD
%_NN
to_TO
$_$
0.94_CD
for_PIN
the_DT
full_JJ
year_NN
neuroscience_NN
,_,
and_ANDC
respiratory_JJ
and_CC
inflammation_NOMZ
important_JJ
Nexium_NN
sales_NN
reached_VBD
$_$
3.9_CD
billion_CD
,_,
up_RB
15_CD
%_NN
areas_NN
of_PIN
healthcare_NN
that_TSUB
represent_VPRT
the_DT
majority_NOMZ
of_PIN
the_DT
worldwide_JJ
Seroquel_NN
sales_NN
increased_VBN [WZPAST]
by_PIN
33_CD
%_NN
to_TO
just_EMPH
over_IN
$_$
2_CD
billion_CD
burden_NN
of_PIN
disease_NN
._.
We_FPP1
have_VPRT
a_DT
broad_JJ
range_NN
of_PIN
products_NN
for_PIN
Symbicort_NN
sales_NN
totalled_VBD
$_$
797_CD
million_CD
,_,
up_RB
32_CD
%_NN
these_DEMO
areas_NN
and_CC
a_DT
commitment_NOMZ
to_TO
delivering_VBG
a_DT
flow_NN
of_PIN
new_JJ
Expanded_VBN
use_NN
of_PIN
Arimidex_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
early_TIME
stage_NN
breast_NN
cancer_NN
medicines_NN
designed_VBN
to_TO
meet_VB
the_DT
underpinned_VBN
48_CD
%_NN
increase_NN
in_PIN
sales_NN
to_TO
$_$
811_CD
million_CD
needs_NN
of_PIN
patients_NN
and_CC
the_DT
healthcare_NN
professionals_NN
who_WP [WHSUB]
treat_VPRT
them_TPP3
._.
Crestor_NN
sales_NN
totalled_VBD
$_$
908_CD
million_CD
despite_PIN
challenging_JJ
environment_NOMZ
._.
Sales_NN
impacted_VBN [WZPAST]
by_PIN
allegations_NOMZ
regarding_VBG [WZPRES]
the_DT
products_NN
safety_NN
._.
Clinical_JJ
trials_NN
experience_NN
and_CC
post-marketing_JJ
surveillance_NN
continue_VPRT
to_TO
support_VB
our_FPP1
belief_NN
that_TOBJ
the_DT
safety_NN
profile_NN
is_VPRT [BEMA]
in_PIN
line_NN
with_PIN
other_JJ
marketed_VBN
statins_NN
FDA_NN
decision_NN
not_XX0
to_TO
approve_VB
Exanta_NN
._.
In_PIN
the_DT
EU_NN
,_,
where_RB
Exanta_NN
already_RB
marketed_VBD
for_PIN
acute_JJ
indications_NOMZ
,_,
more_EMPH
data_NN
have_VPRT [PEAS]
been_VBN [PASS]
requested_VBN [SUAV]
before_IN
approval_NN
of_PIN
use_NN
in_PIN
chronic_JJ
indication_NOMZ
can_POMD
be_VB [PASS]
considered_VBN [PRIV]
Results_NN
of_PIN
ISEL_NN
clinical_JJ
study_NN
for_PIN
Iressa_NN
showed_VBD [PRIV]
no_DT
statistically_RB
significant_JJ
increase_NN
in_PIN
survival_NN
of_PIN
overall_JJ
population_NOMZ
._.
Data_NN
suggest_VPRT [SUAV] [PUBV]
survival_NN
benefits_NN
in_PIN
patient_JJ
populations_NOMZ
of_PIN
East_PLACE
Asian_JJ
origin_NN
and_PHC
non-smokers_NN
R&D_NN
investment_NOMZ
totalled_VBD
$_$
3.8_CD
billion_CD
._.
40_CD
%_NN
more_EMPH
projects_NN
in_PIN
clinical_JJ
development_NOMZ
phases_NN
1_CD
and_CC
2_CD
than_PIN
in_PIN
2003_CD
._.
31_CD
projects_NN
in_PIN
pre-clinical_JJ
testing_GER
26_CD
in_PIN
2003_CD
Important_JJ
strategic_JJ
alliance_NN
with_PIN
Cambridge_NN
Antibody_NN
Technology_NN
to_TO
discover_VB [PRIV]
and_PHC
develop_VB
human_JJ
antibody_NN
therapeutics_NN
in_PIN
inflammatory_JJ
disorders_NN
Global_JJ
clinical_JJ
trials_NN
website_VPRT
on_PIN
track_NN
for_PIN
launch_NN
in_PIN
the_DT
first_JJ
quarter_NN
of_PIN
2005_CD
._.
This_DEMP
will_PRMD
provide_VB
a_DT
detailed_JJ
,_,
publicly_RB
available_JJ
,_,
scientific_JJ
,_,
non-promotional_JJ
summary_NN
of_PIN
clinical_JJ
trials_NN
conducted_VBN [WZPAST]
for_PIN
products_NN
approved_VBN
since_OSUB
AstraZeneca_NN
was_VBD [PASS]
formed_VBN
in_PIN
1999_CD
Appointment_NOMZ
of_PIN
Executive_NN
Director_NN
for_PIN
Development_NOMZ
as_IN
part_NN
of_PIN
accelerated_VBN
significant_JJ
program_NN
of_PIN
change_NN
to_TO
optimise_VB
the_DT
contribution_NOMZ
of_PIN
our_FPP1
development_NOMZ
and_CC
regulatory_JJ
functions_NOMZ
Contents_NN
Chairmans_NN
statement_NOMZ
02_CD
Board_NN
of_PIN
Directors_NN
18_CD
Strategy_NN
03_CD
Summary_NN
Directors_NN
report_VPRT [PUBV]
20_CD
Chief_NN
Executives_NN
review_VPRT
04_CD
Remuneration_NOMZ
policy_NN
22_CD
Financial_NN
highlights_VPRT
05_CD
Summary_NN
financial_JJ
review_NN
24_CD
AstraZeneca_NN
in_PIN
brief_JJ
05_CD
Summary_NN
financial_JJ
statements_NOMZ
27_CD
Discovery_NN
07_CD
Auditors_NN
statement_NOMZ
27_CD
Development_NOMZ
08_CD
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
28_CD
Development_NOMZ
pipeline_NN
09_CD
Group_NN
balance_NN
sheet_NN
30_CD
Sales_NN
and_PHC
marketing_GER
10_CD
Statement_NOMZ
of_PIN
Group_NN
cash_NN
flow_NN
31_CD
Key_NN
products_NN
10_CD
Dividends_NN
32_CD
Supply_NN
12_CD
Earnings_GER
per_PIN
share_NN
32_CD
Product_NN
strategy_NN
&_CC
licensing_GER
13_CD
Emoluments_NOMZ
of_PIN
Directors_NN
33_CD
People_NN
14_CD
Group_NN
financial_JJ
record_NN
34_CD
Therapy_NN
area_NN
review_NN
16_CD
Shareholder_NN
information_NOMZ
35_CD
